Company Quick10K Filing
OWC Pharmaceutical Research
10-Q 2019-09-30 Filed 2019-11-13
10-Q 2019-06-30 Filed 2019-08-13
S-1 2019-05-31 Public Filing
10-Q 2019-03-31 Filed 2019-05-15
10-K 2018-12-31 Filed 2019-04-01
10-Q 2018-09-30 Filed 2018-11-08
10-Q 2018-06-30 Filed 2018-08-16
S-1 2018-06-14 Public Filing
10-Q 2018-03-31 Filed 2018-05-15
10-K 2017-12-31 Filed 2018-04-16
10-Q 2017-09-30 Filed 2017-11-14
10-Q 2017-06-30 Filed 2017-08-21
10-Q 2017-03-31 Filed 2017-05-18
10-K 2016-12-31 Filed 2017-04-17
10-Q 2016-09-30 Filed 2016-11-14
10-Q 2016-06-30 Filed 2016-08-29
10-Q 2016-03-31 Filed 2016-05-16
10-K 2015-12-31 Filed 2016-04-14
10-Q 2015-09-30 Filed 2015-11-13
10-Q 2015-06-30 Filed 2015-08-17
10-Q 2015-03-31 Filed 2015-05-15
10-K 2014-12-31 Filed 2015-04-01
10-Q 2014-09-30 Filed 2014-11-14
10-Q 2014-06-30 Filed 2014-07-29
10-Q 2014-03-31 Filed 2014-05-08
10-K 2013-12-31 Filed 2014-03-21
10-Q 2013-09-30 Filed 2013-11-07
10-Q 2013-06-30 Filed 2013-08-12
10-Q 2013-03-31 Filed 2013-05-14
10-K 2012-12-31 Filed 2013-04-15
8-K 2020-08-31 Shareholder Vote
8-K 2020-06-25 Officers, Other Events
8-K 2020-06-21
8-K 2020-03-30
8-K 2020-03-19
8-K 2020-03-12
8-K 2020-03-09
8-K 2019-12-20
8-K 2019-12-12
8-K 2019-11-13
8-K 2019-11-13
8-K 2019-10-22
8-K 2019-10-07
8-K 2019-09-16
8-K 2019-08-29
8-K 2019-07-24
8-K 2019-05-23
8-K 2019-05-06
8-K 2019-04-15
8-K 2019-04-04
8-K 2019-03-13
8-K 2019-02-22
8-K 2019-02-05
8-K 2019-02-01
8-K 2019-01-29
8-K 2018-12-31
8-K 2018-11-30
8-K 2018-11-30
8-K 2018-10-22
8-K 2018-08-21
8-K 2018-08-01
8-K 2018-06-28
8-K 2018-06-13
8-K 2018-04-30
8-K 2018-03-08
8-K 2018-03-05
8-K 2018-02-19

OWC Pharmaceutical Research Financials

OWCP Metrics, Comps, Filings

Quarterly | Annual

Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
OWC Pharmaceutical Research (OWCP) 0 0% -0.2 362% 1,773 1,467 100 0 6,420 6,420 -1,465
Headhunter Group (HHR)
United States Short Oil Fund (DNO) 0 -0% 0.0 0 0 -600 0 -1,856 -1,856 -0
Immune Therapeutics (IMUN) 0 0.0 -29,381% 8 13,479 0 0 -2,476 -2,475 -6
Juniper Industrial (JIH)
PositiveID Corp (PSID)
Live Current Media (LIVC) 0 2.8 -26% 418 108 0 0 -110 -109 -306
Sun Pacific Holding (SNPW) 0 30% -17.5 -20% 6,669 10,975 260 77 -1,301 -315 5,510
Digatrade Financial (DIGAF) 0 0% 527 778 0 0 0 0 0
Lingerie Fighting Championships (BOTY) 0 -49% 0.2 -8,950,200% 23 -11 90 -10 -2
New Century Resources (NCRE) 0 0.0 0 205 0 0 -18 -17 -0
Arete Industries (ARET)
Renewable Energy Acquisition (REAC) 0 0.0 2,353,600% 0 0 -24 -22 -0
Sundial Growers (SNDL)
Energy Transfer Operating (ETP) 0 27% 5.8 4% 95,247,000 59,636,000 40,493,000 10,886,000 3,786,000 8,016,000 46,523,000
Blue Line Protection Group (BLPG) 0 40% 0.0 -189% 1,661 5,917 3,017 1,201 -3,138 -2,534 -19
ABCO Energy (ABCE) 0 38% 0.1 -173% 411 1,359 1,627 622 -713 -502 -28
Guided Therapeutics (GTHP) 0 332% 0.1 1,462% 404 16,413 28 93 5,908 6,835 439
Endonovo Therapeutics (ENDV) 0 73% -0.8 -301% 3,414 19,980 204 150 -10,268 -9,617 7,448
Dominovas Energy (DNRG)

Balance Sheet ($'000)2013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash4178298471,3891,4691,166799532357266162904721,3801,1139716924,6494,2193,4642,8001,8401,465
Accounts Receivable
Inventory
PP&E26292928262318371411104633333373353331
Assets4178298471,4371,5231,1958405684303432391304972,0761,4131,2181,0617364,7744,3123,5532,9492,3351,773
Accounts Payable12173753459853640657112823198163104286
Long-Term Debt
Liabilities741021284981604056471083153512373964481762082702346,4246,76810,76710,2511,7501,467
Stockholders' Equity-57-947981,3561,4631,15478552132328-150-1071011,6271,2371,010791502-2,183-3,791-9,440-10,242-3,043-4,008
Income Statement ($'000)2013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue00000000000000050000010001000
Cost of Revenue
Gross Profit
R&D0000000160997797-15373530-2443421694-782155273126285320168
SG&A59149149472-1074,3541543055333112452228475-2,3871,4011,5581,106-6,851821756543498395519
Tax0000000000
Net Income-71-170-42-35-509-4,354-315-405-408-233-314-80-141-1,658-1,435-445-1,201-1,477-977-2,990-991-1,0007,707-287
Cash Flow ($'000)2013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-19-49-14-9-17-22-289-274-3871,138-1,795-173-172-100-126-131-191-395-274-326-371-949-427-665-955-372
Cash Investing-6-2-2010-10-2-6-10-10-20-20
Cash Financing156354238608593539002410710505251,768-273101891054,9180000